An Aggressive Trade in Array Biopharma

When the market gets volatile, I like the lower correlation biotech offers. While equities have managed to remain in a range, albeit testing the top and bottom within the same day more often than not, we still have strong charts in some individual stocks. Despite biotech losing a bit of its former headline grabbing attention, there are still plenty of great setups to be found. 

Array Biopharma (ARRY) is one of those names that fits the mold. The stock has been trending higher throughout 2018 offering a few opportunities to grab shares on the long side each time it revisits support. It may seems a bit counterintuitive to look at shares today since we are trading closer to resistance rather than support, but the breakout from the recent bull flag hints at higher prices before resistance comes into play. I'm looking for a move to the $20 area from this $18 breakout level. Support of $17.75 along with $16.50 should shield significant downside in technical terms, but as with almost any biotech, a fundamental surprise can hit at almost any time....103 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.